02092-A: Developing the Use of a Novel Imaging Technique to Define a Dog's Potential Responsiveness to Chemotherapy
Grant Status: Closed
Abstract
Lymphoma is one of the most common cancers in pet dogs. Although this cancer responds well to chemotherapy, the duration of cancer remission and survival time afforded by chemotherapy differ dramatically from dog to dog, with some dogs' cancers responding less favorably to chemotherapy than others. Unfortunately, there are no current tests that can predict the response of an individual dog's cancer to chemotherapy. A method to accurately predict the likelihood and duration of cancer remission provided by specific chemotherapy drugs would be extremely valuable for identifying those dogs most likely to benefit from chemotherapy and for selecting the best drugs to treat individual dogs' cancers. This would allow "personalized" treatment for individual dogs with lymphoma. Dr. Childress will test a new technology called biodynamic imaging (BDI) for its ability to predict the response of canine multicentric lymphoma to doxorubicin, the most potent chemotherapy drug for treating this cancer. BDI data will be compared with clinical response to chemotherapy to determine how well BDI predicts the likelihood and duration of cancer remission. The study results study will be used to plan larger follow-up studies to further develop BDI as a method for personalizing chemotherapy treatment for dogs with lymphoma.
Publication(s)
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
